Abstracts

T-CELL AND MONOCYTE ACTIVATION CORRELATE AND DECLINE DURING HCV THERAPY FOR HCV/HIV

Immune activation predicts morbidity in HCV, HIV and HCV-HIV co-infection despite antiretroviral therapy (ART). HCV DAA therapy is associated with partial/complete normalization of soluble markers of immune activation during HCV infection. How this extends to cellular immunity during HCV-HIV infection is less clear. We analyzed plasma and PBMC from AIDS Clinical Trials Group (ACTG) A5329,…

LIVER FIBROSIS HINDERS NORMALIZATION OF SYSTEMIC INFLAMMATION AFTER HCV ERADICATION

HCV co-infection significantly impacts on inflammation, endothelial activation and coagulation function parameters leading to several comorbidities among people living with HIV (PLWH). The new direct-acting antivirals (DAAs) therapy achieves eradication of HCV in the majority of patients. However, the early effect of HCV eradication on these parameters on PLWH has been scarcely explored. We have…

TELOMERE LENGTH OF CIRRHOTIC HIV/HCV PATIENTS INCREASES AFTER HCV CLEARANCE WITH DAAs

Human immunodeficiency virus (HIV) infection and cirrhosis are associated with a senescent phenotype that decreases telomere length. We evaluated the impact of hepatitis C virus (HCV) elimination on telomere length in patients with advanced HCV-related cirrhosis after sustained virological response (SVR) with all-oral direct-acting antiviral agents (DAAs). Prospective study of 60 HIV/HCV-coinfected and 30 HCV-monoinfected…

LIVER STIFFNESS FOR PORTAL HYPERTENSIVE GASTROINTESTINAL BLEEDING AFTER HCV CURE

Among patients with active HCV-infection, values of liver stiffness (LS)<21 kPa identify individuals without risk of developing portal hypertensive gastrointestinal bleeding (PHGB).Thus, this LS level has been incorporated to some management algorithm of HCV-infected patients,so that upper gastrointestinal endoscopy (UGE) is safely spared in those with LS<21 kPa.However, there is no information about its predictive…